You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2024

Details for Patent: 10,603,384


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,603,384 protect, and when does it expire?

Patent 10,603,384 protects PREVYMIS and is included in one NDA.

This patent has fifty-two patent family members in thirty-six countries.

Summary for Patent: 10,603,384
Title:Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
Inventor(s): Paulus; Kerstin (Ratingen, DE), Schwab; Wilfried (Velbert, DE), Grunder; Dominique (Belp, CH), Van Hoogevest; Peter (Neustadt an der Weinstrasse, DE)
Assignee: AICURIS GMBH & CO. KG (Wuppertal, DE)
Application Number:14/381,290
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,603,384

Introduction

United States Patent 10,603,384, like any other patent, is a complex document that outlines the invention, its scope, and the claims that define the intellectual property protected by the patent. Here, we will delve into the key aspects of this patent, including its claims, scope, and the broader patent landscape.

Patent Overview

The patent in question, U.S. Patent 10,603,384, is titled and describes a specific invention, which could be related to methods, products, or processes. To analyze this patent, one must start by understanding the invention itself.

Claims Analysis

Independent and Dependent Claims

Patent claims are the heart of any patent, as they define the scope of the invention. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details[3].

  • Independent Claims: These claims are crucial as they set the broad boundaries of the invention. For U.S. Patent 10,603,384, the independent claims would outline the core aspects of the invention.
  • Dependent Claims: These claims narrow down the invention by adding specific limitations or features to the independent claims. They help in defining the invention more precisely and can be used to differentiate the invention from prior art.

Claim Length and Count

Research has shown that the length and count of independent claims can be indicative of the patent's scope and quality. Generally, narrower claims with fewer words and fewer claims overall tend to have a higher probability of grant and a shorter examination process[3].

Patent Scope

Breadth of Claims

The scope of a patent is determined by the breadth of its claims. Broader claims cover a wider range of variations of the invention, while narrower claims are more specific and limited.

  • Broad Claims: These can be risky as they may overlap with existing patents or be too vague to be enforceable. For example, the Supreme Court has emphasized the importance of enabling any person skilled in the art to make and use the invention, which can be challenging with overly broad claims[2].
  • Narrow Claims: These are more specific and less likely to be invalidated but may not provide as much protection against variations of the invention.

Claim Clarity

Claim clarity is another critical aspect of patent scope. Clear and concise claims are more likely to be upheld in court and provide better protection for the inventor. The enablement requirement under 35 U.S.C. §112(a) ensures that the patent specification is detailed enough for a person skilled in the art to make and use the invention[2].

Enablement Requirement

The enablement requirement is a fundamental aspect of patent law. It mandates that the patent specification must describe the invention in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the invention. This requirement ensures that the public benefits from the disclosure of new technologies and innovations[2].

Patent Eligibility

Patent eligibility under 35 U.S.C. §101 is another crucial factor. The patent must be directed to a new and useful process, machine, manufacture, or composition of matter, or any improvement thereof. The Supreme Court has clarified that patent protection does not extend to laws of nature, natural phenomena, and abstract ideas unless they are integrated into something more[5].

Terminal Disclaimers and Patent Term Adjustments

In some cases, patents may involve terminal disclaimers or patent term adjustments (PTA) and extensions (PTE). These can affect the patent's expiration date and its overall scope. For instance, the Federal Circuit has held that PTA and PTE are treated differently in the context of obviousness-type double patenting (ODP) analysis, with PTA being calculated after the addition of any granted adjustment, while PTE is calculated from the original expiration date before the addition of any extension[1].

Examination Process

The examination process at the U.S. Patent and Trademark Office (USPTO) plays a significant role in shaping the final scope of the patent. The process tends to narrow the scope of patent claims, especially in terms of claim length and count, over the duration of the examination[3].

Forward Citations and Patent Maintenance

Forward citations and patent maintenance payments can also provide insights into the patent's scope and quality. Patents with more forward citations are generally considered more influential and of higher quality. Similarly, the payment of maintenance fees indicates the patent holder's continued interest in maintaining the patent's validity[3].

Industry and Market Impact

The scope and claims of U.S. Patent 10,603,384 also have implications for the industry and market. Broad and clear claims can provide strong protection against competitors, while overly broad or vague claims may lead to litigation and potential invalidation.

Key Takeaways

  • Claims Definition: The claims define the scope of the patent and must be clear, concise, and enabling.
  • Patent Scope: The breadth and clarity of claims determine the patent's scope and its enforceability.
  • Enablement Requirement: The patent specification must enable any person skilled in the art to make and use the invention.
  • Patent Eligibility: The patent must be directed to eligible subject matter under 35 U.S.C. §101.
  • Terminal Disclaimers and PTA/PTE: These can affect the patent's expiration date and are treated differently in ODP analysis.
  • Examination Process: The USPTO examination process tends to narrow the scope of patent claims.

Frequently Asked Questions (FAQs)

Q1: What is the importance of independent claims in a patent? Independent claims define the broad boundaries of the invention and set the foundation for all other claims.

Q2: How does the enablement requirement impact patent claims? The enablement requirement ensures that the patent specification is detailed enough for a person skilled in the art to make and use the invention, which is crucial for the validity and enforceability of the patent.

Q3: What is the difference between PTA and PTE in the context of ODP analysis? PTA is calculated after the addition of any granted adjustment, while PTE is calculated from the original expiration date before the addition of any extension.

Q4: How does the USPTO examination process affect patent claims? The examination process tends to narrow the scope of patent claims, especially in terms of claim length and count, over the duration of the examination.

Q5: What are forward citations, and how do they relate to patent scope? Forward citations indicate the influence and quality of a patent. Patents with more forward citations are generally considered more influential and of higher quality.

Sources

  1. Duanemorris.com: Patent Term Adjustment and Patent Term Extension Analyzed Differently in Consideration of ODP.
  2. Supremecourt.gov: Amgen Inc. v. Sanofi.
  3. Hoover.org: Patent Claims and Patent Scope.
  4. Googleapis.com: United States Patent - US10603384.
  5. Cafc.uscourts.gov: Natural Alternatives International, Inc. v. Creative Compounds, LLC.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,603,384

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-001 Nov 8, 2017 RX Yes Yes 10,603,384 ⤷  Subscribe Y ⤷  Subscribe
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-002 Nov 8, 2017 RX Yes Yes 10,603,384 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,603,384

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2012 101 680Feb 29, 2012
PCT Information
PCT FiledFebruary 28, 2013PCT Application Number:PCT/EP2013/054114
PCT Publication Date:September 06, 2013PCT Publication Number: WO2013/127970

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.